Advertisement

International Journal of Hematology

, Volume 75, Issue 3, pp 222–227 | Cite as

Hematopoietic Cell Transplantation as a Form of Immunotherapy

  • Frederick R. Appelbaum
Progress in Hematology

Abstract

The association of graft-versus-host disease with diminished relapse rates following allogeneic hematopoietic cell transplantation, together with the dramatic responses sometimes seen following donor lymphocyte infusions, demonstrates the considerable power of the human immune system to eradicate hematological malignancies.The development of methods that reliably achieve complete engraftment of donor lymphohematopoiesis without subjecting patients to very-high-dose toxic chemoradiotherapy represents an important step in capitalizing on the allogeneic graft-versus-tumor effect. Nonmyeloablative hematopoietic cell transplantation can achieve complete chimerism in essentially all patients with HLA-matched siblings and the large majority of patients with matched unrelated donors. It can be carried out with relative safety, even in patients aged up to 70 years. Enduring complete responses have been seen in patients with virtually all varieties of hematological malignancies. Current studies are defining the role of this procedure in patient management.The greater challenge is to further capitalize on this approach by segregating the graft-versus-tumor effect from graft-versus-host disease.

Key words

Transplantation Immunotherapy Engraftment Graft-versus-tumor 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Barnes DWH, Corp MJ, Loutit JF, Neal FE. Treatment of murine leukaemia with x-rays and homologous bone marrow: preliminary communication.Br Med J. 1956;2:626–627.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts.N Engl J Med. 1979;300:1068–1073.CrossRefPubMedGoogle Scholar
  3. 3.
    Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED, the Seattle Marrow Transplant Team. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation.N Engl J Med. 1981;304:1529–1533.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation.Blood. 1990;75:555–562.PubMedGoogle Scholar
  5. 5.
    Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients: European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia.Blood. 1995;86:2041–2050.PubMedGoogle Scholar
  6. 6.
    Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens.Blood. 1990;76:1867–1871.PubMedGoogle Scholar
  7. 7.
    Ferrara JL. Pathogenesis of acute graft-versus-host disease: cytokines and cellular effectors [review].J Hematother Stem Cell Res. 2000;9:299–306.CrossRefPubMedGoogle Scholar
  8. 8.
    Brochu S, Rious-Masse B, Roy J, Roy DC, Perreault C. Massive activation-induced cell death of alloreactive T cells with apoptosis of bystander postthymic T cells prevents immune reconstitution in mice with graft-versus-host disease.Blood. 1999;94:390–400.PubMedGoogle Scholar
  9. 9.
    Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells.Science. 1999;285:412–415.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Storb R, Yu C, McSweeney P. Mixed chimerism after transplantation of allogeneic hematopoietic cells. In: Thomas ED, Blume KG, Forman SJ, eds.Hematopoietic Cell Transplantation. 2nd ed. Boston, Mass: Blackwell Science; 1999:287–295.Google Scholar
  11. 11.
    Stewart FM, Zhong S, Wuu J, Hsieh C, Nilsson SK, Quesenberry PJ. Lymphohematopoietic engraftment in minimally myeloablated hosts.Blood. 1998;91:3681–3687.PubMedPubMedCentralGoogle Scholar
  12. 12.
    McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.Blood. 2001;97:3390–3400.CrossRefPubMedGoogle Scholar
  13. 13.
    Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.Blood. 2001;97:631–637.CrossRefPubMedGoogle Scholar
  14. 14.
    Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.Blood. 1998;91:756–763.PubMedGoogle Scholar
  15. 15.
    Nagler A, Slavin S, Varadi G, Naparstek E, Samuel S, Or R. Allo-geneic peripheral blood stem cell transplantation using a fludara-bine-based low intensity conditioning regimen for malignant lym-phoma.Bone Marrow Transplant. 2000;25:1021–1028.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Nagler A, Aker M, Or R, et al. Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation.Exp Hematol. 2001;29:362–370.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Childs R, Clave E, Contentin N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses.Blood. 1999;94:3234–3241.PubMedGoogle Scholar
  18. 18.
    Horwitz ME, Barrett AJ, Brown MR, et al. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft.N Engl J Med. 2001;344:881–888.CrossRefPubMedGoogle Scholar
  19. 19.
    Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.N Engl J Med. 2000;343:750–758.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Spitzer TR, McAfee S, Sackstein R, et al. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies.Biol Blood Marrow Transplant. 2000;6:309–320.CrossRefPubMedGoogle Scholar
  21. 21.
    Khouri I, Saliba R, Giralt S, et al. Allogeneic hematopoietic transplantation for indolent lymphomas: improved outcome with non-myeloablative versus high dose chemotherapy (HDCT) regimens [abstract].Blood. 2000;96 (pt 1):199a. Abstract 853.Google Scholar
  22. 22.
    Petersdorf EW, Gooley TA, Anasetti C, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient.Blood. 1998;92:3515–3520.PubMedGoogle Scholar
  23. 23.
    Anasetti C, Bidwell BJ, Martin PJ, Yu XZ. Anti-CD3 F(AB’)2 prevents graft-versus-host disease by selectively depleting donor T cells activated by recipient alloantigens [abstract].Blood. 2000;96(pt 1):582a. Abstract 2499.Google Scholar
  24. 24.
    Perez VL, Van Parijs L, Biuckians A, Zheng XX, Strom TB, Abbas AK. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement.Immunity. 1997;6:411–417.CrossRefPubMedGoogle Scholar
  25. 25.
    Yu XZ, Bidwell SJ, Martin PJ, Anasetti C. CD28-specific antibody prevents graft-versus-host disease in mice.J Immunol. 2000;164:4564–4568.CrossRefPubMedGoogle Scholar
  26. 26.
    Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens.Blood. 1999;93:2336–2341.PubMedGoogle Scholar
  27. 27.
    Warren EH, Greenberg PD, Riddell SR. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution.Blood. 1998;91:2197–2207.PubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2002

Authors and Affiliations

  1. 1.Fred Hutchinson Cancer Research Center and the University of Washington School of MedicineSeattle, WashingtonUSA

Personalised recommendations